Search Results 2861-2870 of 18262 for rheumatoid arthritis

  1. Medical Research & Education - Mayo Clinic News Network

    ... arthritis. Kevin Punsky. December 6, 2016. First · Previous ... 275 · 276 · 277 · 278 · 279 · 280 · 281 ... Next · Last · Sign up to receive email notifications ...

  2. Dexamethasone in Total Knee Arthroplasty - Mayo Clinic

    Inflammatory arthritis; Current systemic fungal infection. Renal or liver failure. Prior adverse reaction to corticosteroid. Primary TKA requiring hardware ...

  3. Radial vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH) - Mayo Clinic

    ... factor Xa or IIa inhibitors ≤ 24 h before procedure - Planned staged PCI within 30 days after index procedure. - Any planned surgeries within 30 days after ...

  4. CAST-AI: Cystectomy after systemic therapy with ADC and Immunotherapy - Mayo Clinic

    ... factor (TNF) or anti-interleukin (IL)-6 agents are excluded * Participants still recovering from toxicity of prior anticancer therapy which was received ...

  5. A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495) - Mayo Clinic

    Has confirmation that epidermal growth factor receptor- (EGFR-), anaplastic lymphoma kinase- (ALK-), c-ros oncogene 1- (ROS1-), or B isoform of rapidly ...

  6. Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis - Mayo Clinic

    Patients must have adequate bone marrow function as defined by the following within 28 days prior to registration: ANC ≥ 1,000 cells/mcl without growth factor ...

  7. Head and neck cancers - Doctors and departments - Mayo Clinic

    ... Arthritis, Thyroid cancer, Thyroid nodule, Abscess, Liver problems, Hepatocellular carcinoma, Infection, Bone metastasis, Pneumothorax, Pleural effusion ...

  8. RLY-2608-201-Ph2 Study of RLY-2608 in PROS and PIK3CA Driven Malformations - Mayo Clinic

    Participation eligibility · Received neutrophil growth factor support within 14 days of the first dose of RLY-2608. · Requires treatment with a prohibited ...

  9. A Study to Investigate LYL845 in Adults With Solid Tumors - Mayo Clinic

    Factor Xa inhibitors - Pregnant or nursing (lactating) women. Note: Other protocol defined Inclusion/Exclusion criteria may apply. Eligibility last updated ...

  10. A Study to Evaluate LY3484356 Alone or Combined with Anticancer Therapies to Treat Patients with Breast or Endometrial Cancer - Mayo Clinic

    Part C: ER+, human epidermal growth factor receptor 2 positive (HER2+) breast cancer with evidence of locally advanced unresectable or metastatic disease ...